
Research Team
Nicholas Harrison, MPH, MA
Contact
Focus Areas
Degrees
MPH, Boston University School of Public Health
MA, Boston University School of Medicine
BS, The Ohio State University
Nicholas contributes health policy and scientific expertise to the Margolis Center’s biomedical innovation and evidence development portfolio. Nicholas engages collaborative research and convening activities with the Center for Drug Evaluation and Research (CDER) at the U.S. FDA to advance and promote regulatory science and the more efficient development of safe and effective drugs for patients in need. Nicholas also contributes to projects that advance policy to incentivize the development and stewardship of priority antibiotics to combat antimicrobial resistance.
Nicholas is broadly interested in the design and implementation of policy that supports the effectiveness and continued evolution of evidence-based practice, with particular interest in medical innovation and primary care. Nicholas is a pharmacologist turned public health professional and is adept in evaluating the components of complex systems and communicating detailed messages to stakeholders across the healthcare landscape, from policy-makers and regulators to care-providers and patients.
White Paper
Recommended Post-Market Incentive Strategies to Support the Development of Innovative Antibiotics
Monika Schneider, Nicholas R. Harrison, Mark McClellan
2020
Read MorePolicy Brief
COVID-19 Vaccines: Ensuring Regulatory and Scientific Integrity During the Approval Process
Nicholas R. Harrison, Adam Kroetsch, William Bleser, Morgan Romine, and Mark McClellan
2020
Read MorePolicy Brief
Brief on the Challenges to Sustainable Antibiotic Development
Nicholas R. Harrison & Monica Schneider
2020
Read MoreBlog Entry
Population-Based Payments May Help Ensure Access To Life-Saving Antibiotics For Medicare Beneficiaries
Monika Schneider, Nicholas R. Harrison, Mark B. McClellan
2020
Read MorePolicy Brief
Delinking US Antibiotic Payments through a Subscription Model in Medicare
Monika Schneider, Gregory W. Daniel, Nicholas R. Harrison, Mark B. McClellan
2020
Read MorePolicy Brief
Leveraging Clinical Pharmacology to Optimize Drug Development for Nonalcoholic Steatohepatitis (NASH) and Cholestatic Liver Diseases
Nicholas R. Harrison & Sarah Sheehan
2020
Read MoreJournal Article
Methodological and Regulatory Considerations for Updated Guidance on the Pressor Effects of Drugs
Nicholas R. Harrison, Philip T. Sager, Mitchell W. Krucoff, Michael A. Weber, & William B. White
2020
Read MoreWhite Paper
Determining Real-World Data’s Fitness for Use and the Role of Reliability
Nirosha Mahendraratnam, Christina Silcox, Kerra Mercon, Adam Kroetsch, Morgan Romine, Nicholas R. Harrison, Adam Aten, Rachel Sherman, Gregory Daniel, Mark McClellan
2019
Read MoreProject Report
Characterizing the FDA’s Approach to Benefit-Risk Assessment throughout the Medical Product Life Cycle
Nicholas R. Harrison and Sarah Sheehan
2020
Read More
Decision support tools are valuable, but only if consumers understand them and if they are accurate.
— Charlene Wong, MD, MSHP